293 related articles for article (PubMed ID: 32572597)
1. The KBTBD6/7-DRD2 axis regulates pituitary adenoma sensitivity to dopamine agonist treatment.
Liu YT; Liu F; Cao L; Xue L; Gu WT; Zheng YZ; Tang H; Wang Y; Yao H; Zhang Y; Xie WQ; Ren BH; Xiao ZH; Nie YJ; Hu R; Wu ZB
Acta Neuropathol; 2020 Sep; 140(3):377-396. PubMed ID: 32572597
[TBL] [Abstract][Full Text] [Related]
2. DEPTOR inhibits cell proliferation and confers sensitivity to dopamine agonist in pituitary adenoma.
Yao H; Tang H; Zhang Y; Zhang QF; Liu XY; Liu YT; Gu WT; Zheng YZ; Shang HB; Wang Y; Huang JY; Wei YX; Zhang X; Zhang J; Wu ZB
Cancer Lett; 2019 Sep; 459():135-144. PubMed ID: 31176743
[TBL] [Abstract][Full Text] [Related]
3. Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms.
Pivonello C; Patalano R; Negri M; Pirchio R; Colao A; Pivonello R; Auriemma RS
Front Endocrinol (Lausanne); 2021; 12():791633. PubMed ID: 35095761
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas.
Luque GM; Perez-Millán MI; Ornstein AM; Cristina C; Becu-Villalobos D
J Pharmacol Exp Ther; 2011 Jun; 337(3):766-74. PubMed ID: 21406548
[TBL] [Abstract][Full Text] [Related]
5. The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas.
Wang S; Wang A; Zhang Y; Zhu K; Wang X; Chen Y; Wu J
BMC Endocr Disord; 2021 Nov; 21(1):235. PubMed ID: 34814904
[TBL] [Abstract][Full Text] [Related]
6. The long noncoding RNA-H19/miRNA-93a/ATG7 axis regulates the sensitivity of pituitary adenomas to dopamine agonists.
Wu Z; Zheng Y; Xie W; Li Q; Zhang Y; Ren B; Cai L; Cheng Y; Tang H; Su Z; Wu ZB
Mol Cell Endocrinol; 2020 Dec; 518():111033. PubMed ID: 32946927
[TBL] [Abstract][Full Text] [Related]
7. DRD2 expression based on
Tang H; Cheng Y; Lou X; Yao H; Xie J; Gu W; Huang X; Liu Y; Lin S; Dai Y; Xue L; Lin X; Wu ZB
Endocrine; 2023 May; 80(2):419-424. PubMed ID: 36689171
[TBL] [Abstract][Full Text] [Related]
8. Cabergoline and prolactinomas: lack of association between DRD2 polymorphisms and response to treatment.
Bueno C; Trarbach EB; Bronstein MD; Glezer A
Pituitary; 2017 Jun; 20(3):295-300. PubMed ID: 27848079
[TBL] [Abstract][Full Text] [Related]
9. [Role of dopamine receptor subtypes DRD2 and DRD5 in drug therapy of pituitary tumors].
Liu YT; Zhang Y; Wang Y; Wu ZB
Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(22):1703-1706. PubMed ID: 31216815
[No Abstract] [Full Text] [Related]
10. A Novel Mechanism Regulating Dopamine Receptor Type 2 Signal Transduction in Pituitary Tumoral Cells: The Role of cAMP/PKA-Induced Filamin A Phosphorylation.
Mangili F; Treppiedi D; Catalano R; Marra G; Di Muro G; Spada A; Arosio M; Peverelli E; Mantovani G
Front Endocrinol (Lausanne); 2020; 11():611752. PubMed ID: 33664708
[TBL] [Abstract][Full Text] [Related]
11. CUL3-KBTBD6/KBTBD7 ubiquitin ligase cooperates with GABARAP proteins to spatially restrict TIAM1-RAC1 signaling.
Genau HM; Huber J; Baschieri F; Akutsu M; Dötsch V; Farhan H; Rogov V; Behrends C
Mol Cell; 2015 Mar; 57(6):995-1010. PubMed ID: 25684205
[TBL] [Abstract][Full Text] [Related]
12. PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.
Cristina C; Díaz-Torga GS; Goya RG; Kakar SS; Perez-Millán MI; Passos VQ; Giannella-Neto D; Bronstein MD; Becu-Villalobos D
Mol Cancer; 2007 Jan; 6():4. PubMed ID: 17222350
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin receptor sst2 gene transfer in human prolactinomas in vitro: impact on sensitivity to dopamine, somatostatin and dopastatin, in the control of prolactin secretion.
Cuny T; Mohamed A; Graillon T; Roche C; Defilles C; Germanetti AL; Couderc B; Figarella-Branger D; Enjalbert A; Barlier A; Saveanu A
Mol Cell Endocrinol; 2012 May; 355(1):106-13. PubMed ID: 22348806
[TBL] [Abstract][Full Text] [Related]
14. Prolactinomas Resistant to Dopamine Agonists: Pathophysiology and Treatment.
Shimon I
Arch Med Res; 2023 Dec; 54(8):102883. PubMed ID: 37689507
[TBL] [Abstract][Full Text] [Related]
15. Resistant prolactinomas: a case series of 26 patients.
Eshkoli T; Fraenkel M; Zaid D; Cohen D; Yoel U; Tsvetov G; Gorshtein A; Goldbart A; Greenman Y; Shimon I
Endocrine; 2022 Aug; 77(2):349-356. PubMed ID: 35604631
[TBL] [Abstract][Full Text] [Related]
16. Sex differences in the pituitary transforming growth factor-β1 system: studies in a model of resistant prolactinomas.
Recouvreux MV; Lapyckyj L; Camilletti MA; Guida MC; Ornstein A; Rifkin DB; Becu-Villalobos D; Díaz-Torga G
Endocrinology; 2013 Nov; 154(11):4192-205. PubMed ID: 24008346
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical detection of dopamine D2 receptors in human pituitary adenomas.
Pawlikowski M
Folia Histochem Cytobiol; 2010 Sep; 48(3):394-7. PubMed ID: 21071344
[TBL] [Abstract][Full Text] [Related]
18. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
[TBL] [Abstract][Full Text] [Related]
19. The role of TGF-β/Smad signaling in dopamine agonist-resistant prolactinomas.
Li Z; Liu Q; Li C; Zong X; Bai J; Wu Y; Lan X; Yu G; Zhang Y
Mol Cell Endocrinol; 2015 Feb; 402():64-71. PubMed ID: 25578603
[TBL] [Abstract][Full Text] [Related]
20. CircOMA1 modulates cabergoline resistance by downregulating ferroptosis in prolactinoma.
Wu N; Zhu D; Li J; Li X; Zhu Z; Rao Q; Hu B; Wang H; Zhu Y
J Endocrinol Invest; 2023 Aug; 46(8):1573-1587. PubMed ID: 36853491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
